-- Shandong Boan Biotechnology (HKG:6955) said Chinese regulators had accepted the firm's application to conduct a phase 2 trial of BA1106 in lung cancer for review, according to a Hong Kong bourse filing Sunday.
Shares of the pharmaceutical company gained over 2% in morning trade Monday.
The company is seeking approval to study the drug in combination with another of its medicine, BA1104, as a first-line or second-line treatment of non-small cell lung cancer.